CONTENTS

Preface *vii-ix*

SECTION-I: Palladium catalyzed cross-coupling reactions **1-48**

CHAPTER 1. INTRODUCTION 1

1.1. Palladium in synthetic organic chemistry 1
1.2. Types of reactions 2
1.2.1. Heck reaction 4
1.2.2. Regioselectivity in the Heck Reaction 7
1.3. Coupling reactions between nucleophiles and C(sp^2)–X: Negishi, Suzuki, Sonogashira and Buchwald–Hartwig Reactions 8
1.3.1. Negishi Coupling 9
1.3.2. Suzuki coupling 10
1.3.3. Sonogashira coupling 12
1.3.4. Buchwald-Hartwig Coupling: The C-N and C-O coupling 13
1.4. Palladium catalyzed α-arylation of amides 16

CHAPTER 2. RESEARCH ENVISAGED 20

CHAPTER 3. RESULTS AND DISCUSSION 21

CHAPTER 4. EXPERIMENTAL 35

4.1. Synthesis of 1-substituted aryl 4,5-dihydro-3-methyl-1*H*-benzo[*d*]azepin-2-one (**3**) 35
4.1.1. Process A 35
4.1.2. Process B 36
4.1.3. Process C 36
4.1.4. Process D 37
4.1.5. Process E 37
4.1.5.1. 1-(3-Methoxyphenyl)-3-methyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3a**) 38
4.1.5.2. 3-Methyl-1-(3-tolyl)-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3b**) 38
4.1.5.3. 1-(3-(Trifluoromethyl)phenyl)-4,5-dihydro-3-methyl-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3c**) 39
4.1.5.4. 1-(4-Methoxyphenyl)-3-methyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3d**) 39
4.1.5.5. 1-(2-Methoxyphenyl)-3-methyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3e**) 40
4.1.5.6. 3-Methyl-1-(2-tolyl)-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3f**) 41
4.1.5.7. 3-Methyl-1-(4-tolyl)-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3g**) 41
4.1.5.8. 1-(3-Fluorophenyl)-4,5-dihydro-3-methyl-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3h**) 42
4.1.5.9. 1-(4-Fluorophenyl)-4,5-dihydro-3-methyl-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3i**) 42
4.1.5.10. 3-Methyl-1-(3,5-dimethylphenyl)-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3j**) 43
4.1.5.11. 3-Methyl-1-(1-naphthyl)-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3k**) 43
4.1.5.12. 1-(4-Ethylphenyl)-4,5-dihydro-3-methyl-*1H*-benzo[*d*]azepin- 44

2(*3H*)-one (**3l**)
4.1.5.13. 1-(4-Biphenyl)-4,5-dihydro-3-methyl-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3m**) 45
4.2. Synthesis of 1,3-dimethyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**5**) 45
4.3 HPLC Analysis 46

CHAPTER 5. REFERENCES 47

SECTION-II:3-Benzazepine derivatives 49-101

CHAPTER 1. INTRODUCTION 49

1.1. Therapeutic potentials of 5-HT_{2C} receptor modulators 50
1.1.1. Obesity 51
1.1.2. Anxiety 52
1.1.3. Depression 53
1.1.4. Schizophrenia 53
1.1.5. Neurodegenerative disorders 54
1.1.6. Other clinical indications 54
1.2. Benzazepine based 5-HT_{2C} receptor agonists 55

CHAPTER 2. RESEARCH ENVISAGED 60

CHAPTER 3. RESULTS AND DISCUSSION 62

3.1. Chemical studies 62
3.2. Biological studies 70
3.2.1. *In vitro* isolated rat fundus and isolated rat thoracic aorta experiments 70
3.2.2. Tail Suspension Test (TST) in mice 71
3.2.3. Elevated Plus-Maze (EPM) test 73
3.2.4. Hypophagic response in rats 74
3.2.5. Rat model of penile erection 75

CHAPTER 4. EXPERIMENTAL 78

4.1. Chemical studies 78
4.1.1. General procedure for selective alkylation (**2**) 78
4.1.1.1. 1-Allyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**2a**) 79
4.1.2. General procedure for symmetrical alkylation (**3**) 79
4.1.2.1. 1,3-Diethyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3b**) 80
4.1.2.2. 1,3-Dibenzyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3c**) 81
4.1.2.3. 1,3-Diallyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**3d**) 81
4.1.3. General procedure for reduction of amide (**3**) 82
4.1.3.1. 1-Ethyl-3-methyl-2,3,4,5-tetrahydro-*1H*-benzo[*d*]azepine (**4a**) 82
4.1.3.2. 1,3-Diethyl-2,3,4,5-tetrahydro-*1H*-benzo[*d*]azepine (**4b**) 82
4.1.3.3. 1,3-Dibenzyl-2,3,4,5-tetrahydro-*1H*-benzo[*d*]azepine (**4c**) 83
4.1.4. General procedure for selective alkylation of amidic nitrogen (**5**) 83
4.1.4.1. 3-Allyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**5a**) 84
4.1.4.2. 3-Benzyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**5b**) 84
4.1.5. General procedure for differential tri-alkylation (**7**/**8**) 85
4.1.5.1. 1,1,3-Tribenzyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**7a**) 86
4.1.5.2. 1,3-Diallyl-1-benzyl-4,5-dihydro-*1H* benzo[*d*]azepin-2(*3H*)-one (**7b**) 86

4.1.6. General procedure for reduction of amide (**7**) 87
4.1.6.1. 1,1,3-Tribenzyl-2,3,4,5-tetrahydro-*1H*-benzo[*d*]azepine (**8a**) 87

4.1.7. General procedure for mono-/di-alkylation of N-methyl-3-benzazepin-2-one (**9/10**) 87
4.1.7.1. 1-Allyl-3-methyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**9a**) 88
4.1.7.2. 1,1-Diethyl -3-methyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**10a**) 88
4.1.7.3. 1,1-Dibenzyl-3-methyl-4,5-dihydro-*1H*-benzo[*d*]azepin-2(*3H*)-one (**10b**) 89
4.1.8. General procedure for reductive alkylation to obtain (**11-14**) 89
4.1.8.1. 1,1-Diethyl-3-methyl-2,3,4,5-tetrahydro-*1H*-benzo[*d*]azepine (**11a**) 91
4.1.8.2. Ethyl 1-methyl-1,2,4,5-tetrahydro-benzo[*d*]azepine-3-carboxylate (**12a**) 91
4.1.8.3. Ethyl 1-ethyl-1,2,4,5-tetrahydrobenzo[*d*]azepine-3-carboxylate (**12b**) 91
4.1.8.4. Ethyl 1,1-diethyl-1,2,4,5-tetrahydrobenzo[*d*]azepine-3-carboxylate (**12c**) 92
4.1.8.5. 1,1-Dibenzyl-2,3,4,5-tetrahydro-*1H*-benzo[*d*]azepine (**13a**) 92
4.1.8.6. 4-((1-Ethyl-1,2,4,5-tetrahydrobenzo[*d*]azepin-3-yl)methyl)-*N,N*-dimethylbenzenamine (**14a**) 93
4.2. Biological studies 93
4.2.1. *In vitro* 5-HT assay using isolated rat fundus preparation 93
4.2.2. *In vitro* 5-HT assay using isolated rat thoracic aorta strip 94
4.2.3. Tail Suspension Test (TST) in mice 95
4.2.4. Elevated Plus-Maze (EPM) test 95
4.2.5. Hypophagic response in rats 96
4.2.6. Rat model of penile erection 96

CHAPTER 5. REFERENCES 97

SECTION-III: Cyclic Guanidine and Benzamide derivatives 102-206

CHAPTER 1. INTRODUCTION 102

1.1 Alzheimer's Disease (AD) 102
1.1.1. Cholinergic hypothesis 107
1.1.2. Amyloid hypothesis 108
1.1.3. Tau hypothesis 108
1.2. AD pathogenesis: Three current competing hypotheses 109
1.3. Current treatments and recent clinical research for AD 111
1.3.1. Interventions targeting amyloid 112
1.3.1.1. β-Secretase (BACE) inhibitors 112
1.3.1.2. γ-Secretase inhibitors 113
1.3.1.3. Selective $A\beta_{42}$ lowering agents 113
1.3.1.4. Immunotherapy 114
1.3.1.5. Anti-aggregation agents 115
1.3.2. Advanced Glycation End (AGEs) products 115
1.3.3. NMDA receptor antagonists 116
1.3.4. Nerve Growth Factor (NGF) 117
1.3.5. Targeting Tau protein 117
1.3.6. Serotonin receptors 117

CHAPTER 2. RESEARCH ENVISAGED 119

CHAPTER 3. RESULTS AND DISCUSSION 120

3.1. Chemical studies 120
3.2. Biological studies 132
3.2.1. Part A-Anti-Alzheimer's activity 132
3.2.1.1. Cholinesterase inhibition studies 133
3.2.1.2. Inhibition of *h*AChE-induced Aβ aggregation 136
3.2.1.3. SH-SY5Y neuroblastoma cell toxicity 137
3.2.1.4. Molecular modeling (docking) studies 138
3.2.2. Part B-Anti-thrombotic activity 142
3.2.2.1. Evaluation of anti-thrombotic activity after three days treatment 143
3.2.2.2. Evaluation of anti-thrombotic activity after one hour treatment 145
3.2.2.3. Acute oral toxicity study in mice 146
3.2.2.4. Molecular modeling (docking) studies 148

CHAPTER 4. EXPERIMENTAL 153

4.1. Chemical studies 153
4.1.1. General procedure for the synthesis of 2-aminobenzamides (**2**) 153
4.1.1.1. 2-Ethylamino-N-isobutylbenzamide (**2bj**) 154
4.1.1.2. N-(4-Chlorobenzyl)-2-ethylaminobenzamide (**2bq**) 154
4.1.1.3. N-(4-Fluorobenzyl)-2-ethylaminobenzamide (**2br**) 155
4.1.1.4. N-(4-Chlorobenzyl)-2-propylaminobenzamide (**2cq**) 155
4.1.1.5. 2-Allylamino-N-cyclohexylbenzamide (**2dl**) 156
4.1.1.6. 2-Allylamino-N-benzylbenzamide (**2dm**) 157
4.1.1.7. 2-Allylamino-N-phenethylbenzamide (**2ds**) 157
4.1.1.8. 2-Allylamino-N-isopropylbenzamide (**2di**) 158
4.1.1.9. 2-Allylamino-N-butylbenzamide (**2dh**) 158
4.1.1.10. 2-Allylamino-N-cyclopropylbenzamide (**2dk**) 159
4.1.1.11. N-(2-Chlorobenzyl)-2-allylaminobenzamide (**2do**) 159
4.1.1.12. N-(3-Chlorobenzyl)-2-allylaminobenzamide (**2dp**) 160
4.1.1.13. N-(4-Chlorobenzyl)-2-allylaminobenzamide (**2dq**) 160
4.1.1.14. N-(4-Fluorobenzyl)-2-allylaminobenzamide (**2dr**) 161
4.1.1.15. 2-Allylamino-N-isobutylbenzamide (**2dj**) 161
4.1.1.16. 2-Benzylamino-N-phenethylbenzamide (**2es**) 162
4.1.1.17. 2-Benzylamino-N-cyclohexylbenzamide (**2el**) 163
4.1.1.18. 2-Benzylamino-N-cyclopropylbenzamide (**2ek**) 163
4.1.1.19. N-(4-Methoxybenzyl)-2-benzylaminobenzamide (**2en**) 164
4.1.1.20. N-(2-Chlorobenzyl)-2-benzylaminobenzamide (**2eo**) 164
4.1.1.21. N-(4-Chlorobenzyl)-2-benzylaminobenzamide (**2eq**) 165
4.1.1.22. N-(4-Fluorobenzyl)-2-benzylaminobenzamide (**2er**) 165
4.1.1.23. 2-Benzylamino-N-isobutylbenzamide (**2ej**) 166
4.1.2. General Procedures for the synthesis of 1,3-disubstituted -2-imino-2,3-dihydroquinazolin-4(*1H*)-ones (**3**) 166
4.1.2.1. Method 1 166
4.1.2.2. Method 2 167
4.1.2.3. Method 3 167
4.1.2.4. Method 4 167
4.1.2.5. Method 5 168
4.1.2.6. Method 6 168
4.1.2.7. Method 7 169
4.1.2.8. Method 8 169
4.1.2.8.1. 1,3-Dimethyl-2,3-dihydroquinazolin-4(*1H*)-one (**3af**) 169

	4.1.2.8.2.	3-Butyl-2-imino-1-methyl-2,3-dihydroquinazolin-4(*1H*)-one (**3ah**)	170
	4.1.2.8.3.	3-isopropyl-2-imino-1-methyl-2,3-dihydroquinazolin-4(*1H*)-one (**3ai**)	170
	4.1.2.8.4.	3-Cyclohexyl-2-imino-1-methyl-2,3-dihydroquinazolin-4(*1H*)-one (**3al**)	171
	4.1.2.8.5.	3-Benzyl-2-imino-1-methyl-2, 3-dihydroquinazolin-4(*1H*)-one (**3am**)	171
	4.1.2.8.6.	3-(4-Methoxybenzyl)-2-imino-1-methyl-2,3-dihydroquinazolin-4(*1H*)-one (**3an**)	172
	4.1.2.8.7.	1-Ethyl-2-imino-3-propyl-2, 3-dihydroquinazolin-4(*1H*)-one (**3bg**)	172
	4.1.2.8.8.	3-Butyl-1-ethyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3bh**)	172
	4.1.2.8.9.	1-Ethyl-2-imino-3-isopropyl-2,3-dihydroquinazolin-4(*1H*)-one (**3bi**)	173
	4.1.2.8.10.	3-Cyclopropyl-1-ethyl-2-imino-2, 3-dihydroquinazolin-4(*1H*)-one (**3bk**)	174
	4.1.2.8.11.	3-Cyclohexyl-1-ethyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3bl**)	174
	4.1.2.8.12.	3-Benzyl-1-ethyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3bm**)	174
	4.1.2.8.13.	3-(2-Chlorobenzyl)-1-ethyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3bo**)	175
	4.1.2.8.14.	1-Ethyl -2-imino-3-phenethyl-2, 3-dihydroquinazolin-4(*1H*)-one (**3bs**)	175
	4.1.2.8.15.	2-Imino-3-methyl-1-propyl-2,3-dihydroquinazolin-4(i*H*)-one (**3cf**)	176
	4.1.2.8.16.	3-Butyl-2-imino-1-propyl-2,3-dihydroquinazolin-4(*1H*)-one (**3ch**)	176
	4.1.2.8.17.	2-Imino-3-isopropyl-1-propyl-2,3-dihydroquinazolin-4(*1H*)-one (**3ci**)	177
	4.1.2.8.18.	3-Cyclohexyl-2-imino-1-propyl-2,3-dihydroquinazolin-4(*1H*)-one (**3cl**)	177
	4.1.2.8.19.	3-(4-Methoxybenzyl)-2-imino-1-propyl-2,3-dihydroquinazolin-4(*1H*)-one (**3cn**)	178
	4.1.2.8.20.	1-Allyl-3-butyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3dh**)	178
	4.1.2.8.21.	3-(4-Methoxybenzyl)-1-allyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3dn**)	179
	4.1.2.8.22.	1-Benzyl-3-butyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3eh**)	179
	4.1.2.8.23.	1-Benzyl-2-imino-3-isopropyl-2,3-dihydroquinazolin-4(*1H*)-one (**3ei**)	180
	4.1.2.8.24.	1-Benzyl-3-cyclopropyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3ek**)	180
	4.1.2.8.25.	1-Benzyl-3-cyclohexyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3el**)	180
	4.1.2.8.26.	3-(4-Methoxybenzyl)-1-benzyl-2-imino-2,3-dihydroquinazolin-4(*1H*)-one (**3en**)	181
	4.1.2.8.27.	1-Benzyl-2-imino-3-phenethyl-2,3-dihydroquinazolin-4(*1H*)-one (**3es**)	181
4.1.2.9.	Method 9		182
4.1.2.10.	Method 10		182
4.1.2.11.	Method 11		183
4.1.2.12.	Method 12		183
4.1.2.13.	Method 13		184

4.1.2.14. Method 14 184
4.1.2.15. Method 15 185
4.1.2.16. Method 16 185
4.1.2.17. Method 17 185
4.1.2.18. Method 18 185
4.1.2.19. Method 19 186
4.1.3. General Procedure for the synthesis of 4-(substitutedamino)methyl 3-aminobenzoates (**5**) 186
4.1.4. General Procedure for the synthesis of 1-substituted-2-aminoimidazoles (**6**) 187
4.1.4.1. Methyl 1-(4-methoxybenzyl)-2-amino-*1H*-benzo[*d*]imidazole-5-carboxylate (**6n**) 187
4.1.4.2. Methyl 1-(2-chlorobenzyl)-2-amino-*1H*-benzo[*d*]imidazole-5-carboxylate (**6o**) 188
4.1.4.3. Methyl 2-amino-1-phenethyl-*1H*-benzo[*d*]imidazole-5-carboxylate (**6s**) 188
4.1.5. General Procedure for synthesis of substituted 2-aminobenzohydrazides (**8**) 189
4.1.6. General Procedure for the synthesis of 1,4-disubstituted 2-amino-1,2,3,4-tetrahydrobenzo-1,2,4-triazepin-5-ones (**9**) 189
4.1.6.1. 2-Imino-4-phenyl-1-propyl-1,2,3,4-tetrahydrobenzo[*e*]-1,2,4-triazepin-5-one (**9ct**) 190
4.1.6.2. 1-Benzyl-2-imino-4-phenethyl-1,2,3,4-tetrahydrobenzo[*e*]-1,2,4-triazepin-5-one (**9es**) 190
4.2 Biological studies 191
4.2.1. Part A-Anti-Alzheimer's activity 191
4.2.1.1. Cholinesterase inhibition assay 191
4.2.1.2. *h*AChE-induced Aβ aggregation inhibition studies 192
4.2.1.3. SH-SY5Y neuroblastoma cell toxicity studies 193
4.2.1.4. Molecular modeling (docking) studies 194
4.2.2. Part B-Anti-thrombotic activity 194
4.2.2.1. Anti-thrombotic activity (Mouse thrombosis model) 194
4.2.2.2. Bleeding time (BT) 195
4.2.2.3. Coagulation parameters 195
4.2.2.4. Acute toxicity study 196
4.2.2.5. Molecular modeling (docking) studies 197

CHAPTER 5. REFERENCES 199

SUMMARY *I-X*